단백질 공학 시장 : 제품별, 기술별, 단백질별, 최종 용도별 - 세계 예측(2024-2032년)

Global Protein Engineering Market size is projected to accrue over 15.9% CAGR between 2024 and 2032, propelled by substantial investments from startups. The influx of innovative ventures is injecting dynamism into the industry, driving advancements in protein-based therapeutics, industrial enzymes, and biocatalysts. For instance, in November 2023, Dutch-Swiss startup Cradle secured 24 million in its first-round financing to advance its generative AI (GenAI) and synthetic biology platform for crafting protein-based therapeutics and other compounds.

The burgeoning interest from startups also reflects the recognition of the pivotal role of protein engineering in addressing healthcare and industrial challenges. The escalation of these investments is likely to foster a fertile ground for transformative research, promising to reshape the landscape of medicine, biotechnology, and beyond.

The overall market is classified into product, technology, protein type, end-use and region.

In terms of product, the protein engineering industry from the instruments segment is set to record 15.9% CAGR from 2024 to 2032. Cutting-edge tools have grown indispensable for researchers and scientists engaged in the development of novel protein-based therapeutics and industrial enzymes. With the rapid technology advancements, there is a growing need for high-throughput screening systems, protein purification equipment, and analytical instruments to streamline the protein engineering process. The surging focus of manufacturers on innovations to meet the evolving needs will further drive the segment growth.

Based on technology, the protein engineering market revenue from the irrational protein design segment will register a 15.8% CAGR from 2024 to 2032. This innovative approach involves deviating from conventional protein structure principles to create novel functionalities and properties. Researchers are increasingly exploring irrational protein designs to develop tailor-made solutions for diverse applications in therapeutics, and industrial processes. The rising interest in specialized tools, computational models, and expertise will add to the segment expansion.

Europe protein engineering market will showcase 16% CAGR from 2024 to 2032. With a strong focus on biotechnology and healthcare innovation, several European countries are driving advancements in protein-based therapeutics, industrial enzymes, and biocatalysts. The robust ecosystem of research institutions and biotech companies along with the influx of government initiatives are supporting protein engineering research and development across the region. The surging investments in cutting-edge technologies and collaborative projects will also contribute to the regional industry growth. For instance, in March 2024, BRAIN Biotech AG, a prominent German biologizing company, and AMSilk GmbH, a global leader in advanced materials, announced the successful conclusion of the initial phase of their collaborative development effort. Following a year of joint endeavors, they have achieved significant optimization of a natural structural protein.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of protein-deficient diseases
    • 3.2.1.2 Increase in adoption of protein drugs over non-protein drugs
    • 3.2.1.3 Increasing research & development activities in the biopharmaceutical industry
    • 3.2.1.4 Growing funding opportunities for protein engineering
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High costs of protein engineering techniques
    • 3.2.2.2 Limited availability of qualified researchers
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutess
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Reagents
• 5.4 Software & services

Chapter 6 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Irrational protein design
• 6.3 Rational protein design

Chapter 7 Market Estimates and Forecast, By Protein Type, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Insulin
• 7.3 Monoclonal antibodies
• 7.4 Vaccines
• 7.5 Growth factors
• 7.6 Coagulation factors
• 7.7 Interferon
• 7.8 Other protein types

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Academic research institutes
• 8.3 Contract research organizations (CROs)
• 8.4 Pharmaceutical & biotechnology companies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Agilent Technologies, Inc.
• 10.2 Amgen Inc.
• 10.3 Bio-Rad Laboratories, Inc.
• 10.4 Bristol Myers Squibb Company
• 10.5 Bruker Corporation
• 10.6 Danaher Corporation
• 10.7 Genentech, Inc.
• 10.8 Integrated DNA Technologies, Inc.
• 10.9 Lonza Group
• 10.10 Merck KGaA
• 10.11 Thermo Fisher Scientific Inc.
• 10.12 Vertex Pharmaceuticals Incorporated